Recent genome-wide association studies identified a missense variant (p.A165T) in the gene encoding mitochondrial amidoxime-reducing component 1 (mARC1) that is strongly associated with protection against MASLD, cirrhosis, and liver-related mortality; however, the mechanism of this protective effect remains unknown. This evidence concerns the gene MTARC1 and metabolic dysfunction-associated steatotic liver disease.